PMID- 37629227
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230829
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 16
DP  - 2023 Aug 9
TI  - Effects of Etanercept and Adalimumab on Serum Levels of Cartilage Remodeling 
      Markers in Women with Rheumatoid Arthritis.
LID - 10.3390/jcm12165185 [doi]
LID - 5185
AB  - Tumor necrosis factor alpha inhibitor (TNFalphaI) therapy is associated with a 
      significant inhibition of radiographic progression, resulting in improved 
      physical function and quality of life among patients with rheumatoid arthritis 
      (RA). The mechanism by which TNFalphaI prevent joint destruction is still unknown. In 
      this study, the effect of 15-month anti-TNF-alpha therapy in combination with 
      methotrexate on circulating levels of biochemical markers of cartilage turnover 
      in female RA patients was assessed. Serum levels of collagen type II C-terminal 
      cleavage neoepitope (C2C), C-terminal propeptide of type II collagen (PIICP), 
      cartilage oligomeric matrix protein (COMP), and matrix metalloproteinase-3 
      (MMP-3) were evaluated using immunoassays at baseline and 15 months after the 
      start of TNFalphaI treatment. Baseline COMP, C2C, and MMP-3 levels and C2C/PIICP 
      ratios were significantly higher in women with RA compared with those observed in 
      the healthy subjects. No differences in PIICP levels between the controls and the 
      women with RA were observed. After 15 months of TNFalphaI treatment, serum levels of 
      C2C, COMP, and MMP-3 decreased, whereas the levels of PIICP increased but were 
      still not different from those of the controls. These changes were accompanied by 
      significantly reduced C2C/PIICP ratios. Before the start of TNFalphaI therapy, serum 
      levels of COMP significantly correlated with the patients' ages (p < 0.05) and 
      their 28-joint disease activity score values based on their erythrocyte 
      sedimentation rates (DAS28-ESR; p < 0.05). Moreover, multiple linear regression 
      analysis showed that baseline COMP levels retained a significant association with 
      DAS28-ESR value (beta = 287.74, p = 0.022, R(2) model = 0.25) after model 
      adjustments. The largest area under the ROC curve was obtained for C2C/PIICP 
      ratios (AUC: 0.830, 95% CI: 0.727-0.932, p < 0.001). Our results suggest that 
      long-term anti-TNF-alpha therapy combined with MTX has a beneficial effect on 
      cartilage remodeling that is associated with clinical improvement among RA 
      patients. Serum C2C/PIICP ratios may help to monitor the effectiveness of 
      anti-TNF-alpha treatment among RA patients.
FAU - Szeremeta, Anna
AU  - Szeremeta A
AUID- ORCID: 0000-0001-8445-2490
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 
      Jednosci 8, 41-200 Sosnowiec, Poland.
FAU - Jura-Poltorak, Agnieszka
AU  - Jura-Poltorak A
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 
      Jednosci 8, 41-200 Sosnowiec, Poland.
FAU - Zon-Giebel, Aleksandra
AU  - Zon-Giebel A
AD  - Department of Rheumatology and Rehabilitation, Specialty Hospital No. 1, 
      Zeromskiego 7, 41-902 Bytom, Poland.
FAU - Olczyk, Krystyna
AU  - Olczyk K
AUID- ORCID: 0000-0002-5833-2628
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 
      Jednosci 8, 41-200 Sosnowiec, Poland.
FAU - Komosinska-Vassev, Katarzyna
AU  - Komosinska-Vassev K
AUID- ORCID: 0000-0003-2307-5884
AD  - Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of 
      Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 
      Jednosci 8, 41-200 Sosnowiec, Poland.
LA  - eng
GR  - PCN-2-016/N/2/I/Medical University of Silesia/
GR  - 2013/09/N/NZ5/00815/The National Science Centre Poland/
PT  - Journal Article
DEP - 20230809
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10455345
OTO - NOTNLM
OT  - C2C
OT  - COMP
OT  - MMP-3
OT  - PIICP
OT  - adalimumab
OT  - cartilage remodeling markers
OT  - etanercept
OT  - rheumatoid arthritis
COIS- The authors declare no conflict of interest.
EDAT- 2023/08/26 10:44
MHDA- 2023/08/26 10:45
PMCR- 2023/08/09
CRDT- 2023/08/26 01:18
PHST- 2023/06/29 00:00 [received]
PHST- 2023/07/31 00:00 [revised]
PHST- 2023/08/04 00:00 [accepted]
PHST- 2023/08/26 10:45 [medline]
PHST- 2023/08/26 10:44 [pubmed]
PHST- 2023/08/26 01:18 [entrez]
PHST- 2023/08/09 00:00 [pmc-release]
AID - jcm12165185 [pii]
AID - jcm-12-05185 [pii]
AID - 10.3390/jcm12165185 [doi]
PST - epublish
SO  - J Clin Med. 2023 Aug 9;12(16):5185. doi: 10.3390/jcm12165185.